CTXR NASDAQ
Citius Pharmaceuticals, Inc.
1W: +22.5%
1M: -6.8%
3M: -10.1%
YTD: -39.7%
1Y: -71.9%
3Y: -97.1%
5Y: -99.0%
$0.50
+0.05 (+11.62%)
Weekly Expected Move ±8.9%
$0
$0
$0
$0
$0
Credit Risk of going bust: higher than 92% of companies Debt: 34.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 90%), Citius Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $7.2M against a stock market value of $13.8M.
Distance to default 1.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.7M (short-term plus half of long-term), stock volatility 109.7%; Altman Z'' -8.58. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.05 (down 90%), Citius Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $7.2M against a stock market value of $13.8M.
Distance to default 1.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.7M (short-term plus half of long-term), stock volatility 109.7%; Altman Z'' -8.58. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (24)
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Now Rated “Hold” by Wall Street Brokerages
Brokerages Set Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) PT at $5.00
Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?
12 Health Care Stocks Moving In Monday's Pre-Market Session
Citius Pharmaceuticals GAAP EPS of -$0.95, revenue of $1.7M
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
12 Health Care Stocks Moving In Friday's Intraday Session
What's Behind The Drop In Citius Pharmaceuticals?
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 21.0%
12 Health Care Stocks Moving In Friday's After-Market Session
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
PainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial Comparison